William Blair analyst Matt Phipps has maintained their bullish stance on GMAB stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Matt Phipps has given his Buy rating due to a combination of factors, primarily focusing on the recent FDA approval of Epkinly in combination with rituximab for second-line follicular lymphoma treatment. This approval was granted earlier than expected, indicating strong confidence in the treatment’s efficacy and potential market impact.
Additionally, the approval was supported by positive results from the Phase III EPCORE FL-1 study, which demonstrated significant improvements in progression-free survival and overall response rates compared to the control group. The promising survival trends and the potential for Epkinly to expand into earlier-line lymphoma settings further solidify its role as a key growth driver for Genmab, supporting the Buy rating.
In another report released today, Truist Financial also reiterated a Buy rating on the stock with a $48.00 price target.